Bactrim (Trimethoprim-Sulfamethoxazole): Clinical Overview
Primary Indications
Bactrim is FDA-approved for urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis, shigellosis, Pneumocystis jirovecii pneumonia (treatment and prophylaxis), and traveler's diarrhea 1.
Urinary Tract Infections
- For uncomplicated cystitis in women: Use TMP-SMX 160/800 mg (one double-strength tablet) twice daily for 3 days 2, 3, 4
- This is appropriate only when local resistance rates do not exceed 20% or when the infecting strain is known to be susceptible 2
- For uncomplicated pyelonephritis: 14 days of therapy 3
- Nitrofurantoin and fosfomycin are preferred first-line agents due to lower resistance and minimal collateral damage 2, 4
Pneumocystis jirovecii Pneumonia (PCP)
- Treatment dose: TMP 15-20 mg/kg/day (SMX 75-100 mg/kg/day) IV in 3-4 divided doses for 21 days 5
- Prophylaxis dose: One double-strength tablet daily (preferred) or one single-strength tablet daily 6, 7
- Prophylaxis indicated when CD4+ count <200/μL, unexplained fever >100°F for ≥2 weeks, or history of oropharyngeal candidiasis 6
- Recent evidence supports lower-dose regimens (<15 mg/kg/day) showing similar mortality with significantly fewer adverse reactions (RR: 0.70,95% CI: 0.53-0.91) 8
Skin and Soft Tissue Infections
- For purulent cellulitis and abscesses: TMP-SMX 1-2 double-strength tablets twice daily for 5-6 days 9, 10
- Effective against MRSA 9
- For nonpurulent cellulitis, β-lactams remain preferred as GAS coverage is controversial 10
Pertussis (Alternative Agent)
- Adults: TMP 320 mg/SMX 1,600 mg daily in 2 divided doses for 14 days 11
- Children >2 months: TMP 8 mg/kg/day, SMX 40 mg/kg/day in 2 divided doses for 14 days 11
- Use only when macrolides are contraindicated or not tolerated 11
Prophylaxis in Immunosuppressed Patients
- Consider fluoroquinolones over TMP-SMX for antibacterial prophylaxis in high-risk pediatric cancer patients (children with AML or relapsed ALL) due to superior efficacy in reducing bacteremia and fever 12
- TMP-SMX prophylaxis significantly reduces bacteremia (RR: 0.59) and infection-related mortality (RR: 0.61) but increases TMP-SMX resistance (RR: 2.91) 12
Dosing Regimens
Adults
- Uncomplicated UTI: 160/800 mg (1 DS tablet) PO BID × 3 days
- PCP treatment: TMP 15-20 mg/kg/day IV divided q6-8h × 21 days
- PCP prophylaxis: 160/800 mg (1 DS tablet) PO daily
- SSTI: 160/800 mg (1-2 DS tablets) PO BID × 5-6 days
- Pertussis: 160/800 mg (1 DS tablet) PO BID × 14 days
Pediatric (>2 months)
- General infections: TMP 8-12 mg/kg/day, SMX 40 mg/kg/day in 2 divided doses
- PCP treatment: TMP 15-20 mg/kg/day IV in 3-4 divided doses × 21 days 5
- PCP prophylaxis: Begin at 4-6 weeks of age in HIV-exposed infants 6
Renal Impairment
- CrCl 15-30 mL/min: Reduce dose by 50%
- CrCl <15 mL/min: Contraindicated when renal function cannot be monitored 1
- In renal failure, increase dosing interval to 12 times the serum creatinine level (mg/dL), maximum 48 hours 13
Absolute Contraindications
Do not use Bactrim in patients with 1:
- Known hypersensitivity to trimethoprim or sulfonamides
- History of drug-induced immune thrombocytopenia with TMP or sulfonamides
- Documented megaloblastic anemia due to folate deficiency
- Age <2 months (risk of kernicterus)
- Marked hepatic damage
- Severe renal insufficiency when function cannot be monitored
- Concomitant dofetilide use
Critical Precautions and Monitoring
High-Risk Populations
- Elderly patients: Higher risk of severe adverse events, folate deficiency, and hematologic changes 1
- Renal dysfunction: Monitor serum potassium closely; high-dose TMP causes progressive hyperkalemia 1
- Glucose-6-phosphate dehydrogenase deficiency: Risk of dose-related hemolysis 1
- AIDS patients: Significantly higher incidence of rash, fever, leukopenia, and elevated transaminases compared to non-AIDS patients 1
Electrolyte Monitoring
- Hyperkalemia: Particularly with high-dose therapy (PCP treatment); monitor serum potassium closely 1
- Hyponatremia: Can be severe and symptomatic, especially in PCP treatment; requires evaluation and correction 1
Hematologic Monitoring
- Monitor CBC in patients receiving prolonged therapy
- Folate deficiency effects are reversible with folinic acid 1
- Thrombocytopenia associated with higher serum TMP levels and longer treatment duration 13
Adverse Effects
Common (>10%)
- Nausea, vomiting, anorexia
- Rash (including maculopapular and urticarial)
- Hyperkalemia (especially with high doses)
Serious but Less Common
- Stevens-Johnson syndrome and toxic epidermal necrolysis: Discontinue immediately 11
- Blood dyscrasias: Anemia, thrombocytopenia, neutropenia, agranulocytosis 11, 5
- Hepatic necrosis 11
- Hypoglycemia: Rare in non-diabetics; higher risk with renal dysfunction, liver disease, malnutrition, or high doses 1
- Crystalluria and renal stones: Maintain adequate fluid intake 11
AIDS-Specific Considerations
- Adverse reaction incidence significantly higher in AIDS patients treated for PCP 1
- If rash, fever, or leukopenia develops, strongly consider discontinuation or alternative therapy 1
Resistance Considerations
The 20% resistance threshold is critical: When local E. coli resistance to TMP-SMX exceeds 20%, empirical use for UTI is not recommended 2. TMP-SMX prophylaxis increases resistance in bacteremia isolates (RR: 2.91-3.35) 12, which must be weighed against clinical benefits in high-risk populations.
Drug Interactions
- Dofetilide: Absolute contraindication 1
- Warfarin: Enhanced anticoagulant effect; monitor INR closely
- Methotrexate: Increased methotrexate toxicity
- Oral antidiabetic agents: Enhanced hypoglycemic effects
- Phenytoin: Increased phenytoin levels
- Avoid leucovorin during PCP treatment: May reduce efficacy 1
Special Clinical Scenarios
Fluid Overload Risk
IV formulation requires large volumes of 5% dextrose as diluent, creating risk of fluid overload 14, 13. Monitor carefully in patients with cardiac or renal compromise.
Desensitization
For patients with non-life-threatening reactions who require TMP-SMX (particularly for PCP prophylaxis), consider desensitization or gradual dose escalation 6, 15. Many patients labeled as "allergic" are not truly allergic and can be safely rechallenged 15.